Kyle Bass files IPR challenge to Biogen's blockbuster MS drug, Tecfidera
Earlier on April 22, IPBiz had reported the IPR challenge of Kyle Bass to Imbruvica :
Kyle Bass files IPR against patent related to Imbruvica (Ibrutinib). This followed a challenge to Ampyra, a treatment for multiple sclerosis. Now, Bass has filed another challenge, again related to a drug for MS.
The Boston Business Journal reported on 22 April 2015:
In a filing with the U.S. Patent and Trademark Office today [22 April 2015], the so-called Coalition for Affordable Drugs — which has already challenged patents held by Lexington-based Shire Pharmaceuticals (Nasdaq: SHPG) and Acorda Therapeutics (Nasdaq: ACOR) in New York and Chelsea, Massachusetts — challenged Biogen's patent No. 8,759,393 for Tecfidera by Biogen (Nasdaq: BIIB). That patent covers the twice-a-day dosage of the drug, which is currently Biogen’s top seller.
from Hedge fund manager targets patent for Biogen's blockbuster MS drug, Tecfidera
See also previous IPBiz post
Hedge funds and patents
Kyle Bass files IPR against patent related to Imbruvica (Ibrutinib). This followed a challenge to Ampyra, a treatment for multiple sclerosis. Now, Bass has filed another challenge, again related to a drug for MS.
The Boston Business Journal reported on 22 April 2015:
In a filing with the U.S. Patent and Trademark Office today [22 April 2015], the so-called Coalition for Affordable Drugs — which has already challenged patents held by Lexington-based Shire Pharmaceuticals (Nasdaq: SHPG) and Acorda Therapeutics (Nasdaq: ACOR) in New York and Chelsea, Massachusetts — challenged Biogen's patent No. 8,759,393 for Tecfidera by Biogen (Nasdaq: BIIB). That patent covers the twice-a-day dosage of the drug, which is currently Biogen’s top seller.
from Hedge fund manager targets patent for Biogen's blockbuster MS drug, Tecfidera
See also previous IPBiz post
Hedge funds and patents
posted by Lawrence B. Ebert at 1:10 PM
0 Comments:
Post a Comment
<< Home